DeCure for Disabling pansclerotic morphea of childhood
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for disabling pansclerotic morphea of childhood — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDisabling pansclerotic morphea of childhood maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for disabling pansclerotic morphea of childhood is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Fourteen children with generalised morphea affecting all levels of skin and soft tissue were examined in 1980, and the term "acral pansclerotic morphea" was used to describe the distribution and depth of sclerosis. Biopsies in some cases showed lymphocytic inflammation and hyaline panniculitis. Laboratory findings included polyclonal elevation of gamma-globulin and peripheral eosinophilia. Pulmonary changes were found in five patients and oesophageal changes in one, suggesting that mild nonprogressive visceral involvement can occur. The authors stated that although cyclophosphamide may retard the process, no satisfactory treatment for progressive, mutilating acral pansclerotic morphea had been found.
A 2020 case report described a four-year-old female child with pansclerotic morphea involving the right upper limb. The disease was resistant to treatment and caused major functional and aesthetic damage. The report noted that pansclerotic morphea can follow a comparatively benign course with spontaneous resolution, or can lead to progressive disability.
No controlled trial data exist for this condition. The 1980 series of fourteen children remains the largest reported group, and no subsequent study has identified a reliably effective therapy. The 2020 single case confirms that treatment resistance and severe disability still occur.
What is missing is any randomised trial, any prospective cohort large enough to test a drug, and any validated biomarker to stratify patients by risk of progression. Without funding for multicentre collaboration and a standardised outcome measure, no drug can be meaningfully evaluated for this rare disease.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Dermatology · 1980 · 116 citations
Disabling Pansclerotic Morphea of Children
AbstractFourteen children with generalized morphea involving all levels of the skin and soft tissues were examined. The term "acral pansclerotic morphea" describes the distribution and the multiple levels of sclerosis. Lymphocytic inflammation and hyaline pannicultitis were observed on biopsy specimens in some cases. Laboratory data were characterized by a polyclonal elevation of gamma-globulin level and by peripheral eosinophilia. Pulmonary changes in five patients and esophageal changes in one imply that acral pansclerotic morphea may be assoicated with mild nonprogressive visceral change. Although cyclophosphamide may retard the process, no satisfactory treatment for progressive, mutilating acral pansclerotic morphea has been found.
Abstract• Fourteen children with generalized morphea involving all levels of the skin and soft tissues were examined. The term "acral pansclerotic morphea" describes the distribution and the multiple levels of sclerosis. Lymphocytic inflammation and hyaline panniculitis were observed on biopsy specimens in some cases. Laboratory data were characterized by a polyclonal elevation of γ-globulin level and by peripheral eosinophilia. Pulmonary changes in five patients and esophageal changes in one imply that acral pansclerotic morphea may be associated with mild nonporgressive visceral change. Although cyclophosphamide may retard the process, no satisfactory treatment for progressive, mutilating acral pansclerotic morphea has been found. (<i>Arch Dermatol</i>116:169-173, 1980)
Greater South Information System · 2020 · 0 citations · open access
Pansclerotic morphea: a historical case in children
AbstractMorphea is a variant of localized scleroderma in which lesions are usually limited to the skin and subcutaneous tissue.Pansclerotic morphea is a rare atrophying and sclerosing type of morphea.It can follow a comparatively benign course with spontaneous resolution of symptoms, or sometimes can lead to a variety of complications resulting in progressive disability.We report a case of pansclerotic morphea in an 4-year-old female child involving the right upper limb, resistant to treatment and the cause of a major functional and esthetic damage.
Greater South Information System · 2020 · 0 citations · open access
Pansclerotic morphea: a historical case in children
AbstractMorphea is a variant of localized scleroderma in which lesions are usually limited to the skin and subcutaneous tissue.Pansclerotic morphea is a rare atrophying and sclerosing type of morphea.It can follow a comparatively benign course with spontaneous resolution of symptoms, or sometimes can lead to a variety of complications resulting in progressive disability.We report a case of pansclerotic morphea in an 4-year-old female child involving the right upper limb, resistant to treatment and the cause of a major functional and esthetic damage.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
